These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 2081897)
21. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R; CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649 [TBL] [Abstract][Full Text] [Related]
22. High-dose naloxone in older normal subjects: implications for Alzheimer's disease. Tariot PN; Gross M; Sunderland T; Cohen MR; Weingartner H; Murphy DL; Cohen RM J Am Geriatr Soc; 1988 Aug; 36(8):681-6. PubMed ID: 3042841 [TBL] [Abstract][Full Text] [Related]
23. Effect of L-tryptophan on memory in patients with schizophrenia. Levkovitz Y; Ophir-Shaham O; Bloch Y; Treves I; Fennig S; Grauer E J Nerv Ment Dis; 2003 Sep; 191(9):568-73. PubMed ID: 14504565 [TBL] [Abstract][Full Text] [Related]
24. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. De Jesus Moreno Moreno M Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119 [TBL] [Abstract][Full Text] [Related]
25. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Villardita C; Grioli S; Lomeo C; Cattaneo C; Parini J Neuropsychobiology; 1992; 25(1):24-8. PubMed ID: 1603291 [TBL] [Abstract][Full Text] [Related]
26. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. Chatellier G; Lacomblez L BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926 [TBL] [Abstract][Full Text] [Related]
27. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. Rainer M; Kraxberger E; Haushofer M; Mucke HA; Jellinger KA J Neural Transm (Vienna); 2000; 107(12):1475-81. PubMed ID: 11459000 [TBL] [Abstract][Full Text] [Related]
28. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Sahakian BJ; Owen AM; Morant NJ; Eagger SA; Boddington S; Crayton L; Crockford HA; Crooks M; Hill K; Levy R Psychopharmacology (Berl); 1993; 110(4):395-401. PubMed ID: 7870908 [TBL] [Abstract][Full Text] [Related]
29. Ondansetron in the treatment of cognitive decline in Alzheimer dementia. Dysken M; Kuskowski M; Love S; Am J Geriatr Psychiatry; 2002; 10(2):212-5. PubMed ID: 11925283 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775 [TBL] [Abstract][Full Text] [Related]
31. Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. Sunderland T; Tariot PN; Mueller EA; Murphy DL; Weingartner H; Cohen RM Psychopharmacol Bull; 1985; 21(3):676-9. PubMed ID: 3898182 [No Abstract] [Full Text] [Related]
32. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900 [TBL] [Abstract][Full Text] [Related]
34. An ACTH 4-9 analog (Org 2766) and cognitive performance: high-dose efficacy and safety in dementia of the Alzheimer's type. Miller TP; Fong K; Tinklenberg JR Biol Psychiatry; 1993 Feb; 33(4):307-9. PubMed ID: 8386005 [No Abstract] [Full Text] [Related]
35. The effectiveness of amiridin in senile dementia of the Alzheimer's type. Bukatina EE; Grigor'eva IV; Sokol'chik EI Neurosci Behav Physiol; 1993; 23(1):83-9. PubMed ID: 8464548 [No Abstract] [Full Text] [Related]
36. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Agnoli A; Fabbrini G; Fioravanti M; Martucci N Eur Neuropsychopharmacol; 1992 Mar; 2(1):31-5. PubMed ID: 1638171 [TBL] [Abstract][Full Text] [Related]
37. A neuropsychological test battery for use in Alzheimer disease clinical trials. Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658 [TBL] [Abstract][Full Text] [Related]